Auspex upsizes IPO, adds shares; Concert outlines plans to raise $75M from IPO;

@FierceBiotech: Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success. More | Follow @FierceBiotech

@JohnCFierce: Furiex preps for buyout talks after IBS drug looks promising in PhIII. News | Follow @JohnCFierce

@DamianFierce: Big Pharma superteam joins NIH to share data, discover new drugs. Story | Follow @DamianFierce

@EmilyMFierce: Mechanism that boosts bone growth could aid osteoporosis drug design. Article via FierceBiotech Research | Follow @EmilyMFierce

> San Diego-based Auspex Pharmaceuticals is upsizing its IPO and now plans to sell 6 million shares at a range of $10 to $12 a share. Report

> Concert Pharmaceuticals set terms for its $75 million IPO, outlining plans to sell 5 million shares at $14 to $16 each. Report

> Amarantus Bioscience announced "positive" clinical data for eltoprazine in a Phase IIa clinical study of adult attention deficit hyperactivity disorder. Release

Medical Device News

@FierceMedDev: FDA: Kids with diabetes can use DexCom's continuous glucose monitor. Story | Follow @FierceMedDev

@MarkHFierce: Here's my perspective, as a patient, on the pacemaker industry. Editor's corner | Follow @MarkHFierce

@MichaelGFierce: Lupin stakes a claim on the sterile injectables market. News | Follow @MichaelGFierce

@EmilyWFierce: Endo waves goodbye to HealthTronics for $130M. Report | Follow @EmilyWFierce

> Boston Scientific appears to turn a corner as sales growth gains momentum. More

> Thermo Fisher closes $13.6B Life Tech acquisition. Item

Pharma News

@FiercePharma: Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. Story | Follow @FiercePharma

@TracyStaton: From FiercePharmaMarketing: UCB nabs Asian marketing rights to hot Biogen MS drugs. More | Follow @TracyStaton

@EricPFierce: My colleague Mark Hollmer offers a thoughtful analysis of pacemakers after having one put in. Check it out. Item | Follow @EricPFierce

@CarlyHFierce: More Humira sales gains help AbbVie meet forecasts. News | Follow @CarlyHFierce

> Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. More

> Bayer, Roche and GSK cancer meds win nod for special U.K. funding. News

> GlaxoSmithKline's Advair loses share to AstraZeneca's aggressive Symbicort discounts. Story

Biotech Research News

> $40M gift from stem cell agency will fund new genomics initiative. Item

> Exposure to acid turns adult cells into stem cells. More

> Merck halts drug testing on chimpanzees. News

> Mechanism that boosts bone growth could aid osteoporosis drug design. Report

> Stem cell signaling protein spurs cancer spread. Story

> Epilepsy drug reverses fatty liver disease in obese mice. Article

Pharma Manufacturing News

> Daiichi Sankyo is bringing the hammer down on Ranbaxy. More

> Amgen is halting Epogen manufacturing in Colorado. Story

> Abbott is closing a plant in Puerto Rico as Mexico's Neolpharma expands. Article

> Alexion buys vial-filling facility in Ireland. News

> Lupin stakes a claim on the sterile injectables market. Report

> Sources: Recipharm looks at doing an IPO to expand cash. Item

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.